CN100430060C - 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途 - Google Patents

用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途 Download PDF

Info

Publication number
CN100430060C
CN100430060C CNB200380103225XA CN200380103225A CN100430060C CN 100430060 C CN100430060 C CN 100430060C CN B200380103225X A CNB200380103225X A CN B200380103225XA CN 200380103225 A CN200380103225 A CN 200380103225A CN 100430060 C CN100430060 C CN 100430060C
Authority
CN
China
Prior art keywords
chemical compound
group
dimethyl
pyrroles
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380103225XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1711089A (zh
Inventor
T·艾布拉姆斯
L·默里
N·普赖尔
J·M·彻林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of CN1711089A publication Critical patent/CN1711089A/zh
Application granted granted Critical
Publication of CN100430060C publication Critical patent/CN100430060C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
CNB200380103225XA 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途 Expired - Fee Related CN100430060C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42638602P 2002-11-15 2002-11-15
US60/426,386 2002-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100814220A Division CN101259131A (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药

Publications (2)

Publication Number Publication Date
CN1711089A CN1711089A (zh) 2005-12-21
CN100430060C true CN100430060C (zh) 2008-11-05

Family

ID=32326343

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB200380103225XA Expired - Fee Related CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途
CNA2008100814220A Pending CN101259131A (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008100814220A Pending CN101259131A (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药

Country Status (22)

Country Link
US (1) US20040152759A1 (nl)
EP (1) EP1562600A4 (nl)
JP (1) JP2006508981A (nl)
KR (1) KR20050086594A (nl)
CN (2) CN100430060C (nl)
AR (1) AR042042A1 (nl)
AU (1) AU2003290943A1 (nl)
BR (1) BR0315630A (nl)
CA (1) CA2506308A1 (nl)
CO (1) CO5700778A2 (nl)
GT (1) GT200300245A (nl)
MX (1) MXPA05005150A (nl)
NL (1) NL1024779C2 (nl)
NO (1) NO20052578L (nl)
PA (1) PA8588601A1 (nl)
PE (1) PE20040835A1 (nl)
PL (1) PL376954A1 (nl)
RU (1) RU2342140C2 (nl)
TW (1) TW200418837A (nl)
UY (1) UY28081A1 (nl)
WO (1) WO2004045523A2 (nl)
ZA (1) ZA200503841B (nl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7994159B2 (en) * 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
CA2578336C (en) * 2004-07-09 2013-09-24 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
NZ561138A (en) * 2005-03-23 2009-06-26 Pfizer Prod Inc Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CA2620594C (en) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition having improved disintegratability
WO2007031833A2 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research Novel series of imidazolyl substituted steroidal and indan-1-one derivatives
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) * 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
WO2010001167A2 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
US20100143295A1 (en) * 2008-12-05 2010-06-10 Auspex Pharmaceuticals, Inc. Quinazoline inhibitors of egfr tyrosine kinase
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
US9931313B2 (en) * 2012-04-04 2018-04-03 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
EP3470394B1 (en) * 2016-06-09 2022-01-26 Yuki Gosei Kogyo Co., Ltd. Method for preparing 4-(piperidin-4-yl)morpholine
AU2020354787A1 (en) * 2019-09-26 2022-04-14 Starpharma Pty Ltd Therapeutic dendrimer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287132B6 (sk) * 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
AU784266B2 (en) * 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002081466A1 (en) * 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
NO20052578L (no) 2005-05-27
EP1562600A2 (en) 2005-08-17
CO5700778A2 (es) 2006-11-30
RU2342140C2 (ru) 2008-12-27
GT200300245A (es) 2004-06-23
RU2005118417A (ru) 2006-01-20
ZA200503841B (en) 2006-09-27
MXPA05005150A (es) 2005-07-22
AU2003290943A1 (en) 2004-06-15
JP2006508981A (ja) 2006-03-16
TW200418837A (en) 2004-10-01
PA8588601A1 (es) 2004-05-21
NL1024779A1 (nl) 2004-05-18
CN1711089A (zh) 2005-12-21
WO2004045523A2 (en) 2004-06-03
BR0315630A (pt) 2005-08-23
PL376954A1 (pl) 2006-01-09
AR042042A1 (es) 2005-06-08
PE20040835A1 (es) 2004-11-18
NL1024779C2 (nl) 2004-11-09
US20040152759A1 (en) 2004-08-05
KR20050086594A (ko) 2005-08-30
CA2506308A1 (en) 2004-06-03
CN101259131A (zh) 2008-09-10
WO2004045523A3 (en) 2004-09-30
UY28081A1 (es) 2004-06-30
EP1562600A4 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
CN100430060C (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
ES2946507T3 (es) Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
KR20210005222A (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
CN107873032A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CZ2004619A3 (cs) Léčivo pro léčení akutní myeloidní leukemie
ES2744198T3 (es) Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
CN101267816A (zh) 使用氢醌安沙霉素的治疗方法
CN102574852A (zh) Akt抑制剂
JP2016512831A (ja) 重水素化されたパルボシクリブ
CN110461853A (zh) 苯并噻吩雌激素受体调节剂
JP2020526572A (ja) パルボシクリブ及び６−（２，４−ジクロロフェニル）−５−［４−［（３ｓ）−１−（３−フルオロプロピル）ピロリジン−３−イル］オキシフェニル］−８，９−ジヒドロ−７ｈ−ベンゾ［７］アヌレン−２−カルボン酸を含む組み合わせ並びに癌の処置のためのその使用
JP2021534177A (ja) 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
EA026412B1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ c-MET ПРОТЕИНКИНАЗ
CN103502219A (zh) 作为治疗剂的新型小分子
CN102083829A (zh) 改良的Raf抑制剂
JP2014005265A (ja) ピラゾール置換アミノ−ヘテロアリール化合物の誘導体
CN103936762A (zh) 吗啉并喹啉类化合物，其制备方法和用途
WO2012149308A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
CN105377838A (zh) 新抗疟剂
CN104418867A (zh) 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途
WO2022061201A1 (en) Compositions and methods for treating cancer
CN103596953B (zh) 吡啶并萘啶类PI3K和mTOR双重抑制剂及其制备与应用
JP2021534114A (ja) 併用療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082212

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081105

Termination date: 20091214

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1082212

Country of ref document: HK